Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 20, Number 5—May 2014

Research

Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

Suzanne M. MarksComments to Author , Jennifer Flood, Barbara Seaworth, Yael Hirsch-Moverman, Lori Armstrong, Sundari Mase, Katya Salcedo, Peter Oh, Edward A. Graviss, Paul W. Colson, Lisa Armitige, Manuel Revuelta, Kathryn Sheeran, and the TB Epidemiologic Studies Consortium
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.M. Marks, L. Armstrong, S. Mase, TB Epidemiologic Studies Consortium); California Department of Public Health, Richmond, California, USA (J. Flood, K. Salcedo, P. Oh); Texas Department of State Health Services, Tyler, Texas, USA (B. Seaworth, L. Armitige, K. Sheeran); University of Texas Health Science Center, Tyler (B. Seaworth, L. Armitige, K. Sheeran); ICAP/Columbia University, New York, New York, USA (Y. Hirsch-Moverman, P.W. Colson, M. Revuelta); Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss)

Main Article

Table 6

Treatment outcomes of MDR/XDR TB study patients alive at diagnosis, by resistance pattern, California, Texas, and New York City, USA, 2005–2007*

Resistance pattern Completed treatment, % Transferred within United States, % Transferred out of United States, % Lost to follow-up, % Stopped because of side effects, % Died during treatment, %
All, N = 134 78 3 6 2 1 9
INH/RIF/RBT-only, n = 17 59 0 18 6 0 18
INH/RIF/RBT-plus, n = 58 83 3 7 0 0 7
First-line, n = 32 78 0 3 6 3 9
Pre-XDR, n = 22 77 9 0 0 5 9
XDR, n = 5
100
0
0
0
0
0
*MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant TB; INH, isoniazid; RIF, rifampin; RBT, rifabutin.

Main Article

TOP